German Accelerator Life Sciences (GALS) - Advise, Connect, Inspire

German Accelerator Life SciencesGerman Accelerator Life Sciences (GALS) helps young German life science companies succeed in the global market. GALS provides individualized and highly flexible services, tailored towards the specific needs and objectives of startups and emerging companies in the life sciences. Experienced mentors and consultants work with the participating teams to establish networks of potential clients, partners, and investors.

Applicants must be promising emerging life science companies that have great potential to benefit from the GALS program. Companies must have an affiliation with Germany, i.e. incorporated in Germany or with significant operations there. Applicants must develop a product or service in (at least) one of the five supported life science segments: Digital Health, Medical Devices, Diagnostics, Therapeutics, or Platform Technologies. The stage of the company's growth is relevant; the age of the company is not.

Application
The GALS application consists of around 20 questions about your company, team, technology, and business plan. It only takes a couple of hours to complete. We also request that companies submit additional materials with their application, such as a slide deck and a product demo (if available). Companies apply to the GALS program via the F6S platform.

GALS accepts companies into the program on a rolling basis. Companies can apply any time. Applications are reviewed by the Selection Committee every 6-8 weeks. Program start dates are flexible.

Next application deadline: March 31, 2017

The GALS Selection Committee meets approximately every 6-8 weeks to evaluate new applications. GALS then invites selected promising companies to an in-person workshop for a further assessment of their technology/approach and business strategy.

All services provided by GALS are free of charge for program participants, however GALS will not cover any related travel or living expenses.

For further infromation, please visit:
http://germanaccelerator.com/life-sciences/

About the German Accelerator Life Sciences
The German Accelerator Life Sciences (GALS) is an initiative of the German Federal Ministry for Economic Affairs and Energy (BMWi), with the goal of helping German startups and young companies succeed in the global marketplace. GALS offers support in multiple areas, from free office space in the world's leading life science innovation hub, to mentoring and advising from industry experts and experienced leaders. GALS opened its doors in October 2015 and has its headquarters in Cambridge, Massachusetts.

Most Popular Now

Virtual Humans Help Aspiring Doctors Lea…

For medical student Katie Goldrath, the first time delivering difficult health news came when she had to tell a young woman named Robin and her mom, Delmy, that Robin had...

Read more

'Smart Contact Lens Sensor' for Diabetic…

A recent study, affiliated with Ulsan National Institute of Science and Technology (UNIST), South Korea, has proposed the possibility of in situ human health monitoring simply by wearing a contact...

Read more

2017 eHealth Competition Awards SilverCl…

The eHealth Competition is an initiative that rewards the best digital health solutions produced by SMEs across Europe. This edition has been supported by Astrazeneca, Ship2B and Younoodle. This competition...

Read more

ECDC Report Shows Strong Potential of E-…

Twenty one EU/EEA countries have developed or are in the process of developing systems to digitally record information about vaccination, according to a new "ECDC survey report on immunisation information...

Read more

Devicare Raises 3 Million Euros in its C…

Devicare, a company specializing in innovative medical devices for chronic home care patients under Remote Patient Monitoring (RPM), has closed out a seed round of 3 million euros. This funding...

Read more

Successful Conclusion to conhIT 2017, th…

25 - 27 April 2017, Berlin, Germany. As conhIT, which took place from 25 to 27 April in Berlin, came to a close, 500 exhibitors, 9,500 participants from around the world...

Read more

Compiling Big Data in a Human-Centric Wa…

When a group of researchers in the Undiagnosed Disease Network at Baylor College of Medicine realized they were spending days combing through databases searching for information regarding gene variants, they...

Read more

Scopis Introduces the First Mixed-Realit…

Scopis, a company specializing in surgical navigation and medical augmented and mixed reality technologies, announced today the launch of its newest development, the Holographic Navigation Platform for use in surgery...

Read more

IMS MAXIMS Launches Vital Signs Mobile A…

Clinical technology specialist IMS MAXIMS will be launching its fully integrated vital signs application at eHealth Week on 3rd and 4th May in Olympia, London. Delegates will be the first...

Read more

Immunisation Information Systems in the …

Immunisation information systems (IIS) are defined as confidential, population-based, computerised databases that record all immunisation doses administered by participating providers to persons residing within a given geopolitical area. At the...

Read more

Abbott Announces CE Mark and First Use o…

Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will help physicians identify...

Read more

Using a Smartphone to Screen for Male In…

More than 45 million couples worldwide grapple with infertility, but current standard methods for diagnosing male infertility can be expensive, labor-intensive and require testing in a clinical setting. Cultural and...

Read more